Doris M. Kraemer

St. Josefs Hospital Hagen
Hagen, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 42 publications

DECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy.

DECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy.

Journal: BMC cancer

Published: June 16, 2026

Patient characteristics and treatment outcomes in marginal zone lymphoma: results of the prospective German MZL registry.

Patient characteristics and treatment outcomes in marginal zone lymphoma: results of the prospective German MZL registry.

Journal: Leukemia

Published: July 25, 2025

Automated radiomics model for prediction of therapy response and minimal residual disease from baseline MRI in multiple myeloma.

Automated radiomics model for prediction of therapy response and minimal residual disease from baseline MRI in multiple myeloma.

Journal: Scientific reports

Published: March 25, 2025

Role of extracellular vesicles as promotors for activation of leukemia‑derived dendritic cell‑mediated antileukemic immune response against AML‑blasts.

Role of extracellular vesicles as promotors for activation of leukemia‑derived dendritic cell‑mediated antileukemic immune response against AML‑blasts.

Journal: Oncology reports

Published: December 20, 2024

Concentration-dependent effects of immunomodulatory cocktails on the generation of leukemia-derived dendritic cells, DCleu mediated T-cell activation and on-target/off-tumor toxicity.

Concentration-dependent effects of immunomodulatory cocktails on the generation of leukemia-derived dendritic cells, DCleu mediated T-cell activation and on-target/off-tumor toxicity.

Journal: Frontiers in immunology

Published: November 14, 2024

Dendritic/antigen presenting cell mediated provision of T-cell receptor gamma delta (TCRγδ) expressing cells contributes to improving antileukemic reactions ex vivo.

Dendritic/antigen presenting cell mediated provision of T-cell receptor gamma delta (TCRγδ) expressing cells contributes to improving antileukemic reactions ex vivo.

Journal: Molecular immunology

Published: June 20, 2024

Anti-Leukemic Effects Induced by Dendritic Cells of Leukemic Origin from Leukemic Blood Samples Are Comparable under Hypoxic vs. Normoxic Conditions.

Anti-Leukemic Effects Induced by Dendritic Cells of Leukemic Origin from Leukemic Blood Samples Are Comparable under Hypoxic vs. Normoxic Conditions.

Journal: Cancers

Published: May 21, 2024

Effective and Successful Quantification of Leukemia-Specific Immune Cells in AML Patients' Blood or Culture, Focusing on Intracellular Cytokine and Degranulation Assays.

Effective and Successful Quantification of Leukemia-Specific Immune Cells in AML Patients' Blood or Culture, Focusing on Intracellular Cytokine and Degranulation Assays.

Journal: International journal of molecular sciences

Published: February 12, 2024

Prediction of Bone Marrow Biopsy Results From MRI in Multiple Myeloma Patients Using Deep Learning and Radiomics.

Prediction of Bone Marrow Biopsy Results From MRI in Multiple Myeloma Patients Using Deep Learning and Radiomics.

Journal: Investigative radiology

Published: May 24, 2023

Dendritic Cell-Triggered Immune Activation Goes along with Provision of (Leukemia-Specific) Integrin Beta 7-Expressing Immune Cells and Improved Antileukemic Processes.

Dendritic Cell-Triggered Immune Activation Goes along with Provision of (Leukemia-Specific) Integrin Beta 7-Expressing Immune Cells and Improved Antileukemic Processes.

Journal: International journal of molecular sciences

Published: July 04, 2022

Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: a multicentre, prospective, cluster randomised, crossover clinical trial.

Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: a multicentre, prospective, cluster randomised, crossover clinical trial.

Journal: International journal of antimicrobial agents

Published: May 24, 2022

Outcomes of anti-programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real-world analysis.

Outcomes of anti-programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real-world analysis.

Journal: British journal of haematology

Published: February 02, 2022

Showing 1-12 of 42

Last Updated: 09/26/2026